Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,775 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs).
de Boer M, Gosselt HR, Jansen J, van Doorn MBA, Hoentjen F, Nurmohamed MT, Spuls PI, Tas SW, Vonkeman HE, Jessurun NT. de Boer M, et al. Expert Opin Drug Saf. 2023 Mar;22(3):195-202. doi: 10.1080/14740338.2022.2110237. Epub 2022 Aug 10. Expert Opin Drug Saf. 2023. PMID: 35946722
Pessary or cerclage (PC study) to prevent recurrent preterm birth: a non-inferiority, randomised controlled trial.
van Gils AL, van Dijk CE, Koullali B, Lugthart MA, Bet BB, van Zijl MD, van der Weide MC, Knol HM, Martinez de Tejada B, Gordijn SJ, van den Akker ESA, Sueters M, de Boer MA, Hermsen BBJ, de Mooij YM, de Weerd S, van Baal WM, van Hoorn ME, Oudijk MA, Kazemier BM, Mol BWJ, Pajkrt E; PC Research Group. van Gils AL, et al. Among authors: de boer ma. EClinicalMedicine. 2024 Nov 25;78:102945. doi: 10.1016/j.eclinm.2024.102945. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39655284 Free PMC article.
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gión M, Guarneri V, Bianchini G, Wildiers H, Escrivá-de-Romaní S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Harbeck N, et al. Nat Med. 2024 Dec 9. doi: 10.1038/s41591-024-03349-0. Online ahead of print. Nat Med. 2024. PMID: 39653780 No abstract available.
Cost-effectiveness of a randomized controlled trial comparing low-dose aspirin to placebo for the prevention of recurrent preterm birth.
Landman AJEMC, Broulikova HM, Visser L, Nijman TAJ, Hemels MAC, Vollebregt KC, Boormans EMA, Bremer HA, Tuinman E, Langenveld J, van der Made F, Rijnders RJP, van Vliet HAAM, Freeman LM, de Heus R, Blaauw J, Krabbendam I, van de Laar R, Verberg MFG, Scheepers HCJ, Mol BW, de Groot CJM, Oudijk MA, Bosmans JE, de Boer MA. Landman AJEMC, et al. Among authors: de boer ma. Int J Gynaecol Obstet. 2024 Nov 28. doi: 10.1002/ijgo.16024. Online ahead of print. Int J Gynaecol Obstet. 2024. PMID: 39606899
1,775 results